Get Access
TreelipClinical Program Risk Radar
Oncology Phase 2Methodology
NCT00742625

Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Public trial-level signal summary for this oncology Phase 2 record.

Back to reportOpen ClinicalTrials.gov
Record overview

Status and phase

Status: COMPLETED

Phase: PHASE1, PHASE2

Sponsor: National Cancer Institute (NCI)

Condition: Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Untreated Adult Acute Myeloid Leukemia

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: stale_update_signal

Results signal: Low Signal

Operational burden: strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.